List of Fintepla drug patents
Fintepla is owned by Zogenix Inc.
Fintepla contains Fenfluramine Hydrochloride.
Fintepla has a total of 24 drug patents out of which 0 drug patents have expired.
Fintepla was authorised for market use on 25 June, 2020.
Fintepla is available in solution;oral dosage forms.
Fintepla can be used as use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with dravet syndrome; use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with lennox gastaut syndrome, use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome, treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution, use in combination with stiripentol for the treatment of seizures associated with dravet syndrome, use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome, use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome.
The generics of Fintepla are possible to be released after 29 December, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10947183 | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549909 | ZOGENIX INC | Method for the treatment of dravet syndrome |
May, 2033
(10 years from now) | |
| US10478442 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
| US10478441 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US9603815 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US9610260 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
| US9603814 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
|
US9603815
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US10478441
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US10478442
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(10 years from now) | |
|
US9603814
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US9610260
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(10 years from now) | |
|
US9549909
(Pediatric) | ZOGENIX INC | Method for the treatment of dravet syndrome |
Nov, 2033
(10 years from now) | |
| US10950331 | ZOGENIX INC | Control system for control of distribution of medication |
Sep, 2035
(12 years from now) | |
|
US10950331
(Pediatric) | ZOGENIX INC | Control system for control of distribution of medication |
Mar, 2036
(13 years from now) | |
|
US10947183
(Pediatric) | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(14 years from now) | |
| US10603290 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US11040018 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US11406606 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
|
US11040018
(Pediatric) | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(15 years from now) | |
|
US11406606
(Pediatric) | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(15 years from now) | |
|
US10603290
(Pediatric) | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(15 years from now) | |
| US10452815 | ZOGENIX INC | Control system for control of distribution of medication |
Jun, 2038
(15 years from now) | |
|
US10452815
(Pediatric) | ZOGENIX INC | Control system for control of distribution of medication |
Dec, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 25, 2027 |
| New Product (NP) | Jun 25, 2023 |
| New Indication (I) | Mar 25, 2025 |
| Pediatric Exclusivity (PED) | Dec 25, 2027 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome; Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution; Use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with lennox gastaut syndrome; Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome
Dosage: SOLUTION;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic